Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anifrolumab - AstraZeneca

Next Previous
Drug Profile

Anifrolumab - AstraZeneca

Alternative Names: Anifrolumab-fnia - AstraZeneca; Anti-IFNaR MAb - AstraZeneca; MDX-1333; MEDI-546; SAPHNELO; Saphnelo

Latest Information Update: 19 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Developer AstraZeneca; Medarex; MedImmune
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies; Urologics
  • Mechanism of Action Interferon alpha beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Myositis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Systemic lupus erythematosus
  • Phase III Cutaneous lupus erythematosus; Lupus nephritis; Myositis; Scleroderma
  • Phase II Sjogren's syndrome
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 17 Sep 2025 Efficacy and adverse event data from phase III TULIP SC trial in Systemic Lupus Erythematosus released by AstraZeneca
  • 10 Jun 2025 AstraZeneca completes a phase III trial in Systemic lupus erythematosus (Adjunctive treatment) in China, Hong Kong, South Korea, Philippines, Taiwan and Thailand (IV) (NCT04931563)
  • 10 Jan 2025 AstraZeneca completes in a phase I trial (In volunteers) in China (IV, SC) (NCT06662123)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top